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Background: Our aim was to construct a diagnostic model for ruling out chronic thromboembolic pulmonary
hypertension (CTEPH) in symptomatic patients after acute pulmonary embolism (PE) that is based on simple,
non-invasive tests.
Methods: Plasma levels of various CTEPH associated biomarkers and conventional ECG criteria for right
ventricular pressure overload were assessed in 82 consecutive patients with conﬁrmed CTEPH and 160
consecutive patients with a history of PE who were suspected to have CTEPH, but in whom this disease was
ruled out.
Results: ECG criteria of right ventricular hypertrophy were detected more frequently in patients with CTEPH
(77%) than in the patients without CTEPH (11%, Odds ratio 26, 95% conﬁdence interval [CI] 13–53). Also,
clotting factor FVIII activity and the levels of N-terminal-pro-brain-type natriuretic peptide (NT-pro-BNP),
Growth Differentiation Factor-15, C-reactive protein and urate, but not D-dimer level, were higher in patients
with CTEPH. A diagnostic model including ECG criteria and NT-pro-BNP levels had a sensitivity of 94% (95% CI
86-98%) and a speciﬁcity of 65% (95% CI 56-72%). The area under the receiver-operator-characteristic curve
was 0.80 (95% CI 0.74-0.85) for the diagnosis of CTEPH. Even with high disease prevalences of up to 10%, the
negative predictive value of this model proved to be very high (99%, 95% CI 97-100%).
Conclusions: Ruling out CTEPH in patients after acute PE seems to be safe without additional diagnostic testing
in absence of ECG criteria indicative of right ventricular hypertrophy and a normal NT-pro-BNP level.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license. Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH)
results from chronic obstruction of the pulmonary vascular bed by
organized thrombi [1]. The incidence of CTEPH in patients who
suffered from acute pulmonary embolism (PE) has been reported
to be in the range of 0.5-3.8%, depending on the selection criteria
applied in the individual studies [1–6]. The prognosis of patients
with CTEPH is poor, unless a successful pulmonary endarterectomy
is possible [1,7]. Therefore, early recognition of this disease is cruciall Center (C4-70), Albinusdreef
+31 71 5262085; fax: +31 71
vier OA license. for timely referral to a center specialized in the management of
pulmonary hypertension, allowing swift and adequate therapeutical
intervention.
The clinical presentation of CTEPH is characterized by non-
speciﬁc symptoms and include exercise intolerance and dyspnea,
fatigue, chest pain, and syncope (at exercise). These symptoms are
also consistent with other, more common cardiopulmonary condi-
tions such as asthma, chronic obstructive pulmonary disease
(COPD), interstitial lung disease, coronary artery disease, cardiac
arrhythmia or heart failure not caused by chronic pulmonary
thrombi [1,8,9]. These non-speciﬁc symptoms are commonly
reported by patients who suffered from an acute PE and therefore,
the possibility of CTEPH can be frequently considered [10]. The
diagnostic management of CTEPH is complex. In many patients
pulmonary perfusion scintigraphy, transthoracic echocardiography
22 F.A. Klok et al. / Thrombosis Research 128 (2011) 21–26and conventional pulmonary angiography with determination of
pulmonary hemodynamics need to be performed before the
diagnosis of CTEPH can be refuted. There is great need for more
simple, easily available, less invasive and less expensive tests to
safely rule out CTEPH [1]. These tests may include conventional
12-lead electrocardiography (ECG) and biomarkers of heart failure,
inﬂammation or thrombosis that are associated with pathogenesis
or prognosis of CTEPH, andwhicharewidely available for and applicable
to outpatient medical care [11–16]. Although the prognostic value of
these biomarker levels for CTEPH or other entities of pulmonary
hypertension are well described, their diagnostic potential has not been
systematically studied [11–16].
In the present study, we examined whether CTEPH can be ruled
out in symptomatic patients with a documented history of acute PE by
using ECG assessment and measurement of several biomarkers, i.e. N-
terminal-pro-B-type natriuretic peptide (NT-pro-BNP), Growth Dif-
ferentiation Factor-15 (GDF-15), C-reactive protein (CRP), urate,
plasma factor VIII coagulant activity (FVIII:C) and D-dimer, or a com-
bination of these tests.
Materials and methods
Patients
We studied patients from a large follow-up study of patients with
acute PE in an academic (Leiden University Medical Center, Leiden,
the Netherlands) and afﬁliated teaching hospital (Medical Center
Haaglanden, The Hague, the Netherlands) [3]. This study included all
patients who were diagnosed with acute PE between January 2001
and July 2007. The diagnosis of acute PE was based on intraluminal
ﬁlling defects on pulmonary angiography or computed-tomography
pulmonary-angiography (CTPA), high probability ventilation perfu-
sion scintigraphy (VQ-scan) or intermediate probability VQ-scan
in combination with objectively diagnosed deep vein thrombosis
(DVT) [17]. All patients were treated with at least 5 days of either
unfractionated heparin or weight based therapeutic doses of low
molecular weight heparin, followed by vitamin-K antagonists for a
period of at least 6 months. The goal of this study was to determine
the incidence of CTEPH in an large and unselected cohort and in
addition, study the yield of an echocardiography based screening
program for CTEPH. Therefore, we invited all surviving patients who
were no yet diagnosed with pulmonary hypertension at the start of
our study (July 2007) for a single visit to our outpatient clinic for
cardiopulmonary work-up including echocardiography [3]. From the
877 consecutive patients in the original study cohort, 259 had died
before the start of the study, 11 were living abroad and therefore
lost to follow-up, 19 were previously diagnosed with pulmonary
hypertension and 186 declined participation. For the present
analysis, we only studied the remaining patients who were clinically
suspected of having CTEPHbecause they reported exertional dyspnea
and/or decreased exercise capacity.
We additionally included 82 consecutive patients from a CTEPH
referral centre (AcademicMedical Center, Amsterdam, theNetherlands),
who were previously diagnosed with CTEPH by regular clinical care.
This study was approved by the institutional review board of all
participating hospitals and all patients provided written informed
consent.
Procedures
In all three participating centers, the routine diagnostic workup
of patients with suspected CTEPH started with echocardiography.
We used very sensitive echocardiographic criteria for establishing
the suspicion of pulmonary hypertension: 1) estimated systolic
pulmonary artery pressure ≥35 mmHg (maximal pressure gradient
across the tricuspid valve calculated by the modiﬁed Bernoulliequation plus the estimated right atrium pressure, 2) maximal
tricuspid regurgitation velocity N2.8 m/s, 3) borderline value of
criterion 1 or 2 in combination with a right ventricular TEI index
N0.36 (isovolumic contraction time plus isovolumic relaxation time
divided by ejection time), 4) estimated mean pulmonary artery
pressure ≥25 mmHg (estimated systolic pressure plus 2 times
enddiastolic pressure as estimated by pulmonary regurgitation end-
diastolic velocity divided by 3, 5) AcT (acceleration time ) b120 or
AcT/RVET (right ventricular ejection time) b0.40, 6) secondary
changes associated with pulmonary hypertension, e.g. systolic septal
ﬂattening, right ventricular hypertrophy or W-pattern in the right
ventricular outﬂow curve [3]. All patients who met one or more of
these 6 criteria were suspected of having pulmonary hypertension
and underwent further standardized work-up including perfusion
lung scintigraphy and right heart catheterization for pressure
measurements. Criteria for the diagnosis of CTEPH were a mean
pulmonary artery pressure (mPAP) assessed by right heart catheter-
ization exceeding 25 mmHg and a normal pulmonary capillary wedge
pressure in combination with segmental of subsegmental perfusion
defects on perfusion scintigram and signs of CTEPH on conventional
pulmonary angiography [1,18].
All patients were classiﬁed according to the modiﬁed New York
Heart Association (NYHA) classiﬁcation of the World Health
Organization. Conventional 12-lead ECGs were obtained and blood
samples were drawn and stored on the day that the participants of
the follow-up study were screened for pulmonary hypertension, or
before pulmonary endarterectomy was performed or medical
treatment was initiated in the patients with established CTEPH.
The ECGs were recorded with the patient in supine position for a
10-second period using the standard 12-lead electrode conﬁguration
at a conventional speed (25 mm/s) and sensitivity (1 mV/10 mm).
All ECGs were evaluated for the presence of one or more of the
following three criteria of right ventricular hypertrophy that have
been demonstrated by multivariate logistic regression to predict the
presence of pulmonary hypertension optimally: 1) rSR’ or RSr’
pattern in lead V1, 2) R:S N1 in lead V1 with R N0.5 mV and 3) QRS
axis N90° [19].
All blood samples were analyzed in batches after a single thaw.
Levels of NT-pro-BNP were measured with the use of quantitative
immunoassays (Hitachi Modular E 170 unit, Roche Diagnostics,
Mannheim, Germany). GDF-15 serum concentrations were assessed
by immunoradiometric assays using a polyclonal GDF-15 afﬁnity-
chromatography-puriﬁed, goat anti-human GDF-15 IgG antibody
(AF957) from R&D Systems (Minneapolis, MN) [20]. CRP and urate
measurements were performed using A Hitachi Modular system
according the recommendations of the reagent manufacture (Roche,
Diagnostics, Mannheim, Germany). FVIII:C was measured in a one-
stage APTT-based clotting assay using immunodepleted FVIII-
deﬁcient plasma and Automated APTT (BioMerieux, Boxtel, the
Netherlands) on an automated coagulation analyzer (STA-R Evolu-
tion, Diagnostica Stago, Roche Diagnostics). Results for FVIII:C are
expressed as international units (IU) per dL with reference to a
normal pooled plasma calibrated against the 4thWHO international
standard FVIII/VWF plasma (97/586) (NIBSC, Potters Bar, UK). The
D-dimers weremeasured on the same analyzer using the STA-Liatest
D-dimer assay (Diagnostica Stago). The detection range ≥50 pg/mL
for NT-pro-BNP, ≥20 ng/L for GDF-15, ≥1.0 mg/mL for CRP and
≥250≤20000 ng/mL for D-dimer. All biomarker measurements
were performed by investigators who were blinded to the patients'
diagnosis. We used predeﬁned reference values for the biomarkers
under study to predict the presence of CTEPH: NT-pro-BNP
dependent on age and sex as suggested by the manufacturer, GDF-
15≥1200 ng/L, CRP≥3.0 mg/L, uric acid N0.34 mmol/L for female
and N0.42 mmol/L for male patients as suggested by the manufac-
turer, FVIII:C≥150 IU/dL, and D-dimer N500 ng/mL FEU being the
optimal predictor of thrombosis [20–22].
Table 1
Patient characteristics.
Patients with CTEPH (n=82) Patients in whom CTEPH was ruled out (n=160) p-value
Age (years±SD) 57±14 57±16 NS
Male sex (n, %) 32 (39) 73 (46) NS
Active malignancy (n, %) 8 (9.8) 22 (14) NS
COPD (n, %) 6 (7.3) 35 (22) 0.04
Left sided heart disease (n, %) 6 (7.3) 22 (14) b0.001
BMI, kg/m2 (mean, ±SD) 28±6.0 29±5.2 NS
mPAP, mmHg (mean, ±SD) 44±11 - NA
CTEPH=chronic thromboembolic pulmonary hypertension, n=number, SD=standard deviation, COPD=chronic obstructive pulmonary disease, BMI=body mass index, NS=no
statistical signiﬁcance, NA=not applicable, mPAP=mean pulmonary artery pressure.
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We calculated the sensitivity and speciﬁcity of the conventional
ECG criteria of right ventricular hypertrophy and the biomarkers
under study for the presence of CTEPH in all patients. Patients from
the screening study who were identiﬁed as having pulmonary
hypertension of other etiology than CTEPH were excluded from
further analysis. Differences between the study groups were analyzed
using student T-tests for normally distributed continuous variables,
Mann-Whitney-U tests for skewed distributed continuous variables
and chi-square tests for categorical variables. Further, starting with
the clinical test with the highest area under the receiver operator
characteristic (AUC of ROC) curve and thuswith the highest predictive
accuracy, we derived 7 additional clinical models by including
consecutive diagnostic tests with decreasing AUC in a model to
identify the most favorable combination of clinical tests for this pur-
pose. AUC of ROC analyses were compared by the method described
by Hanley and McNeil [23]. Our ﬁnal diagnostic model was based
on the combination of diagnostic tests with the optimal combination
of sensitivity and thus negative predictive value, and speciﬁcity
for efﬁcacy reasons. Finally, we used the following formula to cal-
culate the negative predictive value of the newly constructed optimal
model according to increasing assumed prevalences of CTEPH:
(speciﬁcity*(1-prevelence))/{((1-sensitivity)*prevalence)+(speciﬁci-
ty*(1-prevalence))}. SPSS version 14.02 (SPSS Inc, Chicago, IL) was used




We included 170 patients with a history of acute PE (mean follow-
up period after PE diagnosis 4.5±0.7 years) and clinically suspected
CTEPH. After extensive diagnostic testing including right heart
catheterization and pulmonary scintigraphy, 10 of these 170 patients
were diagnosed with pulmonary hypertension: 5 with COPD
associated pulmonary hypertension and 5 with left heart disease
associated pulmonary hypertension, but none with CTEPH. Therefore,
these 10 patients were excluded from further analysis. Pulmonary
hypertension was ruled out in the remaining 160 patients by either
echocardiography without any signs of pulmonary hypertension orTable 2
Biomarker levels in the study population.
Patients with CTEPH (n=82)
NT-pro-BNP (pg/mL) 756 (161–2563)
GDF-15 (ng/L) 1580 (1058–2741)
CRP (mg/L) 4.5 (1.7-8.3)
Urate (mmol/L) 0.34 (0.24-0.45)
FVIII:C (IU/dL) 2.0 (1.7-2.5)
D-dimer (ng/mL FEU) b250 (b250–432)
Medians and interquartile range are presented. NS=no statistical signiﬁcance.else right heart catheterization indicating normal pulmonary artery
pressure. An alternative explanation for the dyspnea was found in
the majority of the patients, including previously established or
newly diagnosed heart or lung disease, anemia, morbid obesity or a
combination of these conditions [24]. The study population was
completed by 82 consecutive patients with established CTEPH. The
baseline characteristics of the study patients are presented in Table 1.
ECG characteristics and biomarker levels
The typical predeﬁned electrocardiographic signs of pulmonary
hypertension were detected signiﬁcantly more often in patients with
CTEPH (77%) than in the symptomatic patients without pulmonary
hypertension (11%; Odds ratio 26, 95% conﬁdence interval (CI) 13–
53). A closer look at the distribution of the 3 ECG characteristics
revealed that right axis was observedmost frequently in patients with
CTEPH (55%), followed by rSR’ or RSr’ pattern in lead V1 (45%) and R:S
N1 in lead V1 with R N0.5 mV (28%); 31 (38%) patients with CTEPH
had more than one of the three prespeciﬁed ECG characteristics.
Circulating levels of NT-pro-BNP, GDF-15, CRP and Urate were
signiﬁcantly higher in patients with CTEPH than in the other study
group (Table 2 and Fig. 1). On the other hand, D-dimer levels were not
different between the two study groups, with over 50% of the values
beneath the detection level of the used assays (Table 2 and Fig. 1).
Derivation of a diagnostic model
Clear differences between the sensitivity and speciﬁcity and AUC
of the ROC curves were observed between the ECG-characteristics and
the biomarkers under study using these cut-off points (Table 3). The
sensitivity of the ECG criteria (77%, 95% CI 67–86), elevated NT-pro-
BNP levels (82%, 95% CI 72–89) and high FVIII:C (83%, 95% CI 70–92)
were higher than those of elevated GDF-15 (63%, 95% CI 52–74), CRP
(64%, 95% CI 53–75), urate (46%, 95% CI 35–57) and D-dimer levels
(24%, 95% CI 16–35). On the other hand, speciﬁcity was best for the
ECG-criteria (89%, 95% CI 83–93) and elevated urate levels (80%, 95%
CI 73–86). The area under the ROC curve (AUC) was slightly higher
for the ECG-criteria (0.83, 95% CI 0.77-0.89) than for NT-pro-BNP
(difference 0.09, 95% CI −0.04-0.17), and signiﬁcantly higher than
GDF-15 (difference 0.21, 95% CI 0.09-0.30), CRP (difference 0.21, 95%







Fig. 1. Biomarker levels in the 2 study groups. Horizontal bars represent medians. FVIII:C levels were missing for 29 patients with CTEPH. Circles represent patients with CTEPH,
triangles patients without pulmonary hypertension; *pb0.001.
Table 3
Test characteristics of ECG and biomarkers for the diagnosis of CTEPH in symptomatic
patients after acute pulmonary embolism.
Sensitivity (%, 95% CI) Speciﬁcity (%, 95% CI) AUC (95% CI)
ECG criteria† 77 (67–86) 89 (83–93) 0.83 (0.77-0.89)
NT-pro-BNP¶ 82 (72–89) 70 (62–77) 0.74 (0.66-0.82)
GDF-15‡ 63 (52–74) 50 (42–58) 0.62 (0.49-0.64)
CRP¥ 64 (53–75) 61 (52–68) 0.62 (0.53-0.71)
Urate¶ 46 (35–57) 80 (73–86) 0.62 (0.52-0.71)
FVIII:CΔ 83 (70–92) 32 (25–40) 0.57 (0.48-0.66)
D-dimer§ 24 (16–35) 78 (70–84) 0.48 (0.39-0.57)
†Presence of at least 1 of the following criteria: rSR’ or rSr’ pattern in lead V1, R:S N1 in
lead V1 with R N0.5 mV and QRS axis N90°; ¶sex and age dependent threshold;
‡threshold 1200 ng/L; ¥threshold 3.0 mg/L; Δthreshold 150 IU/dL; §threshold 500 ng/mL
FEU. CI=conﬁdence interval, ECG=electrocardiography, AUC=area under the
receiver operator characteristic curve.
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difference 0.35, 95% CI 0.18-0.41; Table 3).
We calculated the additional diagnostic value of the biomarkers to
ECG assessment, which proved to be the most discriminative test for
CTEPH (Table 4). After including NT-pro-BNP to the model (i.e., either
one of the 3 ECG criteria positive or NT-pro-BNP levels elevated), the
sensitivity increased signiﬁcantly (+17%, 95% CI 5.4-29), at the cost ofTable 4
Additional value of biomarkers to ECG assessment for diagnosing CTPEH.
Model Sensitivity (%, 95%
A ECG criteria 77 (67–86)
B NT-pro-BNP+model A 94 (86–98)
C CRP+model B 94 (86–98)
D Urate+model C 94 (86–98)
E GDF-15+model D 96 (90–99)
F FVIII:C+model E 98 (91–99.7)
G D-dimer+model F 99 (93-N99.9)
ECG=electrocardiography, AUC=area under the receiver operator characteristic curve, CIspeciﬁcity (−24%, 95% CI−15 to−33). The AUC of the ROC curve did
not change signiﬁcantly. By including the remaining tests one after
the other to the model, the speciﬁcity decreased considerably to 39%
and even lower, whereas the sensitivity increased only marginally
leading to signiﬁcantly decreased AUC in model C which consists of
ECG assessment, NT-pro-BNP and CRP level measurements (differ-
ence 0.17, 95% CI 0.06-0.30), and in all further models. Therefore, we
determined that model B, which includes ECG-assessment as well as
NT-pro-BNP testing, was the most optimal diagnostic model for ruling
out CTEPH. This model identiﬁed all patients with mPAP greater than
30 mmHg. False negative test result only occurred in a small number
of the patients with relatively mild disease (mPAP between 26 and
30 mmHg). Interestingly, one of these latter patients even had normal
results from all tests.
Effectiveness of the diagnostic model
To test the effectiveness of our diagnostic model, we calculated its
negative predictive value for hypothetically increasing disease
prevalences (Table 5). In case of a normal NT-pro-BNP level and in
the absence of typical ECG characteristics of pulmonary hypertension,
it is very unlikely that a dyspnoeic patient with a history of acute PE
suffers from CTEPH with negative predictive values of 99% or higher,
even in the presence of very high incidences of CTEPH (up to 10%).CI) Speciﬁcity (%, 95% CI) AUC (95% CI)
89 (83–93) 0.83 (0.77-0.89)
65 (56–72) 0.80 (0.74-0.85)
39 (31–47) 0.66 (0.60-0.73)
33 (26–41) 0.64 (0.56-0.71)
23 (17–30) 0.60 (0.53-0.67)
13 (7.8-19) 0.55 (0.48-0.63)
12 (7.3-18) 0.55 (0.48-0.63)
=conﬁdence interval.
Table 5
Negative predictive value of our ﬁnal algorithm (model B) for increasing assumed
prevalences of CTEPH.
Hypothetical incidence of CTEPH Negative predictive value (95% CI)
0.5% 99.9 (99.9- N99.9)
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Our results demonstrate that a simple diagnostic model based on
ECG-evaluation and NT-pro-BNP measurements can rule out CTEPH
with a high level of conﬁdence in patients with a documented history
of acute PE and clinically suspected CTEPH. Additional more expensive
and invasive testing in these patients to rule out CTEPH seems there-
fore not necessary.
The sensitivity of the ECG criteria alone was 77%, which conﬁrms
earlier studies describing the insufﬁcient diagnostic potential of these
ECG criteria for pulmonary hypertension screening purposes [19,25].
The sensitivity, speciﬁcity and AUC of the 3 ECG parameters in our
cohort were even lower than previously reported [19]. This is likely
due to the higher fraction of patients with only mildly elevated mPAP
in our study cohort. NT-pro-BNP levels alone showedslightly higher, but
still insufﬁcient sensitivity for CTEPH. Combining the 3 ECG criteriawith
NT-pro-BNP levels, we obtained a higher sensitivity (94%) with an
acceptable speciﬁcity.
Although the overall prevalence of CTEPH after acute PE -
irrespective of complaints - ranges from 0.5% to 3.8%, this number
likely increases 2 or 3 fold in selected patients with prior acute PE
who present with clinically suspected CTEPH [1–6]. To facilitate
correct interpretation and use of our study results for different clinical
settings and patient cohorts, we observed high negative predictive
value of our diagnostic model for different hypothetical incidences
ranging from 0.5 to 15%, thereby enabling physicians to distinguish
the negative predictive value applicable to their speciﬁc practice.
Importantly, the speciﬁcity of our model was not sufﬁciently high to
conﬁrm CTEPH: patients with suspected CTEPH and one or more ECG
characteristics of pulmonary hypertension or elevated blood levels of
NT-pro-BNP should be subjected to further diagnostic tests, including
echocardiography and right heart catheterization.
Although all biochemical tests under study have been shown to be
correlated to the presence and/or prognosis of pulmonary hyperten-
sion [11–16], and almost all tests were more increased in patients
with CTEPH than in the patients without this disease, their diagnostic
value for CTEPH proved to be limited, with the exception of NT-pro-
BNP. There are 3 plausible explanations for this observation: 1) the
studied biomarkers are especially elevated during acute thrombotic
states (D-dimer, FVIII:C, CRP) or during acute heart failure (NT-pro-
BNP, urate, GDF-15) while CTEPH is a chronic disease characterized by
relatively slow progression, 2) all studied biomarkers are established
prognostic factors for CTEPH and therefore, mostly present in the
patients with severe or worsening disease and 3) a considerable
proportion of our patient population without CTEPH had co-existing
cardiopulmonary and malignant diseases, which are associated with
elevation of one or more of the studied biomarkers as well. For
instance, GDF-15, a stress-responsive, transforming growth factor-β-
related cytokine, is weakly produced under baseline conditions in
most tissues but its production increases sharply in response to
hemodynamic stress, inﬂammation, and tissue injury [26]. Elevatedcirculating levels of GDF-15 have been reported in patients with acute
PE and idiopathic pulmonary arterial hypertension and have been
shown to provide strong and independent prognostic information in
these conditions [11]. However, elevated levels of GDF-15 can also be
detected in other cardiovascular disease states and in patients with
malignant tumors. Therefore, and possibly due to the relatively mildly
elevated mPAP in some of our patients, GDF-15 proved to be a poor
diagnostic test for CTEPH in our population. CRP is a well-known
marker of inﬂammation and tissue damage that recently has been
shown to predict the severity and the outcome in patients with
pulmonary hypertension [12]. Also, serum urate or uric acid, the ﬁnal
product of purine degradation, has been proposed to be a prognostic
marker for hypoxic states such as chronic heart failure and pulmonary
hypertension [13]. Nonetheless, the arguments raised to explain the
limited diagnostic accuracy of GDF-15 can also explain the lack of
discriminative power of urate and CRP levels for CTEPH. Finally, D-
Dimer is a global indicator of coagulation activation and ﬁbrinolysis.
D-dimers and FVIII:C are known to be increased during and after acute
PE, but also in a wide variety of other diseases as infection or
inﬂammatory and malignant conditions [27,28]. Both D-dimer and
FVIII:C were shown to have very limited diagnostic value for CTEPH in
our patient cohort. Altering our pre-deﬁned thresholds for GDF-15,
CRP, urate, FVIII:C or D-dimer did not signiﬁcantly change our
observations (data not shown).
Strengths of this study include the analysis of a large patient cohort
with and without CTEPH and the standardized and blinded assess-
ment of ECG characteristics and biomarker levels, thereby increasing
the likelihood of generalizability of our results and precluding
important biases. Notably, none of the patients with suspected
CTEPH from the screening study was diagnosed with CTEPH. One
important explanation for this low prevalence is that all patients who
were diagnosed with CTEPH prior to the start of our study were
included in the CTEPH cohort and consequently, not in the screening
study. Our study also had limitations. In spite of the narrow con-
ﬁdence intervals, our conclusions should be conﬁrmed in a future
prospective trial since ours was an exploratory but not an outcome
study, and therefore, the sensitivity and speciﬁcity of the diagnostic
tests were calculated retrospectively.
In conclusion, the present study shows that a diagnostic model
based on ECG assessment and NT-pro-BNPmeasurements can be used
to rule out CTEPH in patients with a history of acute PE and clinically
suspected CTEPH. Therefore, more invasive tests to rule out this
disease do not seem necessary in patients without 3 speciﬁc ECG
criteria of right ventricular pressure overload and a normal NT-pro-
BNP level.Disclosures
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